The Food and Drug Administration July 2 authorized for emergency use one more batch of drug substance for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore. To date, the agency has authorized four batches for emergency use after reviewing facility records and results of quality testing performed by the manufacturer. Though the FDA is not ready to include Emergent as an authorized manufacturing facility for the J&J vaccine, the agency said it “continues to work through issues there with Janssen and Emergent BioSolutions management.”

Related News Articles

Headline
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee today by a unanimous vote recommended that the FDA issue an…
Headline
The Centers for Disease Control and Prevention today revealed the comparative effectiveness of the three Food and Drug Administration-authorized COVID-19…
Headline
The Department of Health and Human Services’ Assistant Secretary for Preparedness and Response this week announced a major change in the distribution of…
Headline
The AHA has received a $1 million grant from the Centers for Disease Control and Prevention to continue for one year its efforts to encourage COVID-19…
Headline
A pair of peer-reviewed studies published in the New England Journal of Medicine are affirming the safety and effectiveness of Pfizer’s COVID-19 vaccine, first…
Headline
The Food and Drug Administration yesterday released an updated enforcement policy related to face masks, barrier face coverings, face shields,…